Feature | May 22, 2014

Nearly All ICD Implants Performed on Insured Patients

Majority of ICD patients are also male — new study presented at HRS from more than 160,000 ICD implants

ICD Implants Heart Rhythm Society Clinical Study Insurance Male

May 22, 2014 — A study presented at Heart Rhythm 2014, the Heart Rhythm Society’s 35th Annual Scientific Sessions, reports significant gender and health insurance disparities in implantable cardioverter defibrillator (ICD) procedures. For the first time in nearly a decade, the new analysis of ICD implants in the United States shows a majority of implants are performed on people with insurance and more commonly in the male population.

ICDs are small devices, about the size of a small cell phone, that are placed below the collarbone. Via wires or leads, these devices continuously monitor the heart’s rhythm. If the heart beats too quickly or too slowly, the ICD issues a jolt of electricity to restore the heart’s normal rhythm. People with heart muscle damage or “heart failure” have greater chance of having a dangerously fast heart rhythm that ICDs treat. ICDs are very effective in stopping life-threatening arrhythmias and considered one of the most successful therapies to treat arrhythmias.

The authors of the study queried data from the National Inpatient Sample from 2000-2011 using ICD-9 procedure codes for ICD implantation. ICD utilization was assessed in the following four groups: male insured, male uninsured, female insured and female uninsured. More than 160,000 (160,296) estimated ICD implants were identified in people over the age of 18. Almost all (95 percent) of the ICD implants identified were performed in the insured population. The male population with insurance (70.8 percent) had significantly higher implants compared with the female population with insurance (24.2 percent). Only 5 percent of the procedures were performed on people who did not have insurance.

“The striking results show that major disparities are present with ICD implants and this further highlights the importance of adhering to guidelines, so best possible candidates have access to the life saving device,” said lead author Nileshkumar Patel, MBBS, Staten Island University Hospital in New York. “We are presented with the challenge to look for new ways to enhance the quality of care and continue to educate on the safety and effectiveness of these devices.”

Abhishek Deshmukh, co-author of the study, cardiologist at University of Arkansas for Medical Sciences added, “On the surface, efforts are made toward the mitigation of disparities, but closer examination shows that there is still more work to be done especially in current challenging healthcare landscape.”

For more information: www.HRSonline.org

Related Content

News | Pharmaceuticals| September 26, 2016
Nearly 2 out of 5 people with diabetes who could benefit from statin therapy to lower their risk of future heart attack...
smartphones, hospital tranfers, heart attack patients, JACC study, South Korea
News | Mobile Devices| September 23, 2016
Smartphone communication among medical teams at different hospitals can significantly reduce the time it takes for...
Medtronic, In.Pact Admiral drug-coated balloon, trial data, VIVA
News | Drug-Eluting Balloons| September 22, 2016
New data presented at the Vascular Interventional Advances (VIVA) conference demonstrated the durability, consistency...
Sponsored Content | Videos | Inventory Management| September 21, 2016
With bundled payments putting increased pressure on hospitals to manage supply costs while providing quality patient
Medtronic, CRT, cardiac resynchroniazation therapy devices, heart failure, medication adherence, retrospective analysis, HFSA 2016
News | Heart Failure| September 20, 2016
Medtronic plc announced the results of an analysis that reveals patients increasingly adhere to heart failure...
Valtech Cardio, Cardioband Tricuspid, Cardioband Mitral, PCR London Valves 2016, study data
News | Heart Valve Technology| September 19, 2016
Valtech Cardio Ltd. announced that it will present the first-in-man data for its Cardioband Tricuspid (TR) system at...
don woodlock, GE Healthcare, EP CVIS, electrophyiology
Sponsored Content | Webinar | Cardiac PACS| September 16, 2016
Cardiac rhythm management (CRM) data is becoming increasingly important in the management of patients with implantabl
EBR Systems, FDA, WiSE Technology, Wireless Stimulation Endocardially, SOLVE-CRT study

The WiSE CRT System uses a tiny implant in the left ventricle to synchronize the heart, overcoming limitations of traditional cardiac resynchronization therapy (CRT) in heart failure patients. Graphic courtesy of Business Wire.

News | Cardiac Resynchronization Therapy Devices (CRT)| September 15, 2016
EBR Systems Inc. announced the U.S. Food and Drug Administration (FDA) has granted an Investigational Device Exemption...
News | Cardiac Diagnostics| September 13, 2016
September 13, 2016 — Results from a new study suggest that small molecules known as microRNAs may be part of the path
News | Cardiac Diagnostics| September 13, 2016
September 13, 2016 — Findings from a small...
Overlay Init